ArticleACS nano2019
Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8
Abstract read
In one paragraph
Article in ACS nano, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Intranasal Vaccine Adjuvants and Delivery Platforms: From Barrier Mechanisms to Clinical Translation.Vaccines · 2026Review
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Lipid nanoparticle-based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways.Archives of microbiology · 2025Review
- Review
- Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity.ACS applied materials & interfaces · 2025Article
- Bioengineered nanoparticles for targeted topical delivery in wound healing: advances and future outlook.Nanomedicine (London, England) · 2025Review
- Potentiation of immune checkpoint blockade with a pH-sensitizer as monitored in two pre-clinical tumor models with acidoCEST MRI.British journal of cancer · 2025Article
- Tissue-Resident Memory CD8+ T Cells: Differentiation, Phenotypic Heterogeneity, Biological Function, Disease, and Therapy.MedComm · 2025Review
- Silica-calcium phosphate nanoparticles delivering recombinant influenza hemagglutinin DNA can induce long-lasting T cell immune cross-protection in mice.Frontiers in immunology · 2025Article
- Nanovaccines empowering CD8Theranostics · 2025Review
- Global research trends in the relationship between influenza and CD4Human vaccines & immunotherapeutics · 2024Article
- Advanced technologies for the development of infectious disease vaccines.Nature reviews. Drug discovery · 2024Review
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.Vaccines · 2024Review
- Advancements in cyclodextrin-based controlled drug delivery: Insights into pharmacokinetic and pharmacodynamic profiles.Heliyon · 2024Review
- Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.Pharmaceutics · 2024Article
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.ACS nano · 2024Article
- Nanotechnology of inhalable vaccines for enhancing mucosal immunity.Drug delivery and translational research · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Frances C KnightDepartment of Biomedical Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.ORCID 0000-0001-8892-7262
Pavlo GilchukDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Amrendra KumarDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Kyle W BeckerDepartment of Chemical and Biomolecular Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.ORCID 0000-0003-1627-2724
Sema SevimliDepartment of Chemical and Biomolecular Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.
Max E JacobsonDepartment of Chemical and Biomolecular Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.
Naveenchandra SuryadevaraDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Lihong Wang-BishopDepartment of Chemical and Biomolecular Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.
Kelli L BoydDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
James E CroweDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.ORCID 0000-0002-0049-1079
Sebastian JoyceDepartment of Pathology, Microbiology, and Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
John T WilsonDepartment of Biomedical Engineering , Vanderbilt University , Nashville , Tennessee 37235 , United States.ORCID 0000-0002-9144-2634
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9MMolecular Basis of CD1D and Natural Killer T Cell FunctionR01AI137082 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2019 to 2022
$2.1MProcessing and Presentation of Minor Histocompatibility Antigens that Cause GvHDR01HL121139 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2014 to 2017
$1.6MEngineered Nanoparticles for Protective Subunit Vaccine Delivery and DiscoveryR21AI121626 · NIAID · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2016 to 2017
$418kBLRD Research Career Scientist Award ApplicationIK6BX004595 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2019 to 2025
–Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
–BLRD VA I01 BX001444BLRD VA IK6 BX004595NCI NIH HHS P30 CA068485NHLBI NIH HHS R01 HL121139NIAID NIH HHS R01 AI137082NIAID NIH HHS R21 AI121626NIDDK NIH HHS P30 DK058404
Abstract
Tissue-resident memory T cells (T
Indexed as
Adjuvants, ImmunologicAdministration, IntranasalAnimalsAntigen-Presenting CellsCD8-Positive T-LymphocytesHumansHydrogen-Ion ConcentrationImmunizationImmunogenicity, VaccineImmunologic MemoryInfluenza, HumanLungMiceNanoparticlesT-LymphocytesVaccinesAdjuvants, ImmunologicVaccinesinfluenzaintranasallungsnanoparticlenucleic acid adjuvantsubunit vaccinetissue-resident memory T cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.